New Product: Recombinant GFAP

Published: 25.06.2020

undefinedTraumatic brain injuries are a major public health concern globally. Diagnosis is based on computed tomography, however, injuries are not always visible in these scans. Recent studies support the use of glial fibrillary acidic protein (GFAP) test to help evaluating the need for a CT scan in case traumatic brain injury or concussion is suspected.
Figure 1. SDS-PAGE of recombinant GFAP fragment under reducing conditions in a gradient gel (4-20%). 2.5 μg of purified protein was loaded on the gel.

We have now developed a recombinant GFAP protein that can be used as a standard or calibrator in GFAP immunoassay development. With the recent launch of several anti-GFAP antibodies, we now can provide all key reagents for assay development.

Learn more:
GFAP TechNotes

Cat# 4G25: Glial Fibrillary Acidic Protein, Antibody
Cat# 8G45: Glial fibrillary acidic protein (GFAP), human, recombinant


Sign up to our newsletter

And be informed about new products and scientific findings

Thank you for your subscription!